Take a look at some of Friday's midday movers:
Ann - The women's clothier climbed after its second-quarter revenue forecast beat consensus views.
Apple - The iPhone maker rose after Goldman Sachs raises its price target to $720 from $635 while maintaining its buy rating.
Avery Dennison - The producer of pressure-sensitive materials advanced after JPMorgan upgraded it to overweight from neutral, based on valuation.
Infoblox - The network-equipment maker plunged after forecasting a lower-than-expected profit for the current quarter.
Lowe's Companies - The home-improvement retailer came off its lows after hiking its quarterly dividend nearly 28 percent to 23 cents a share.
Mack-Cali Realty - The real estate investment trust declined after cutting its quarterly dividend 50 percent to 15 cents a share.
Madison Square Garden - The sports, entertainment and media company rose as its New York Rangers hockey team got into the Stanley Cup finals. The proposed sale of the Los Angeles Clippers for $2 billion to former Microsoft CEO Steve Ballmer also helped move the stock higher.
Men's Wearhouse - The retailer and Jos. A Bank Clothiers both rose on a Dow Jones report that the Federal Trade Commission would likely approve their merger.
Michael Kors Holdings - The apparel retailer rose after Canaccord Genuity repeated a buy rating and $123 price target, saying its recent stock weakness is creating a buying opportunity.
Netflix - The online provider of internet programming continued to move higher after bullish comments from CEO Reed Hastings at the re/code conference on Thursday.
Newlink Genetics - The drug developer gained after reporting data from a mid-stage trial of its experimental cancer drug showed positive results.
NPS Pharmaceuticals - The rare disease specialist jumped after a Financial Times blog reported London-listed drugmaker Shire was considering a cash offer for the New Jersey-based company.
NQ Mobile - The Chinese mobile security software maker gained after raising its first-quarter revenue forecast.
Retrophin - The pharmaceutical company rose after licensing marketing rights for a rare kidney disease drug from privately held Mission Pharmacal and hiking its revenue forecast for 2014 and 2015.
(Read More: )
—By CNBC's Rich Fisherman.
Questions? Comments? Email us at marketinsider@cnbc.com